2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5828 High-dimensional immune profiling reveals a B-cell maturation blockage and identifies T-cell senescence as the determinant of response to bispecific antibodies in multiple myeloma

Konstantina Taouxi, Stavroula T. Nikou2, Alexandra Papadimou3, Katerina Chrisostomidou4, Agisilaos Papadopoulos5, Ioannis Kollias6, Eleni Kalafati7, Tina Bagratuni, PhD8, Nikolaos Tsakirakis, MSc9, Panagiotis Bakouros10, Eirini Solia, MD11, Foteini Theodorakakou, MD12, Nikolaos Kanellias, MD, PhD13, Evangelos Eleutherakis Papaiakovou, MD14, Panagiotis Malandrakis, MD, MSc, PhD15, Ioannis Ntanasis-Stathopoulos, MD16, Maria Gavriatopoulou, MD17, Evangelos Terpos, MD18, Meletios-Athanasios (Thanos) C. Dimopoulos, MD19, Ourania Tsitsilonis, MD,PhD20, Efstathios Kastritis, MD21
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
15 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
16 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
17 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
18 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
19 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
20 National and Kapodistrian University of Athens, Athens, Greece
21 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Multiple Myeloma (MM) is a hematological malignancy characterized by the uncontrollable proliferation of plasma cells in the bone marrow (BM). Despite the major therapeutic advances and the continuous development of novel efficient agents, MM remains incurable, with most patients eventually relapsing and developing drug resistance (RRMM). T-cell redirecting therapies, including bispecific antibodies (BsAbs) targeting either BCMA (teclistamab, elranatamab, linvoseltamab) or GPRC5D (talquetamab), exhibit considerable results associated with high overall response rates even in heavily pretreated RRMM patients. Regardless of the encouraging clinical efficacy of BsAbs, treatment response remains poorly understood due to the significant inter-patient heterogeneity. Given that BsAbs’ activity relies on T-cell engagement, characterizing these molecules is fundamental to predict their biological response. Thus, our study aims to perform an in-depth evaluation of immune-mediated elements of response to BsAb therapy, based on high-dimensional immunophenotypic analysis of the immune profile of prospectively enrolled patients treated with BsAbs.

This is an ongoing study enrolling patients with RRMM treated with BsABs according to their approved indications in everyday clinical practice. Fo the current analysis, prospectively collected samples from 25 RRMM patients treated with teclistamab (n=10),  linvoseltamab (n=9)  and talquetamab (n=6) were analyzed using  three-panel, high-dimensional, spectral flow cytometry with a total of 31 different markers. PB was evaluated at baseline, on Cycle 3 Day 1 (C3D1), at Complete Response (CR) and at relapse. Paired BM samples were evaluated at baseline and at CR, when attainable, and at relapse.

Treatment with anti-BCMA BsAbs resulted in a profound and selective disruption of the B-cell maturation associated with significant depletion of transitional CD24+ and activated CD80+ B cells, alongside the expansion of B-cell precursors; this effect was not observed in the talquetamab cohort. Baseline target antigen (BCMA) expression was associated with clinical outcomes: responders exhibited significantly higher BCMA expression on their malignant plasma cells, while, non-responders showed elevated BCMA levels on their B cells in the BM, suggesting that these B cells may act as a "target antigen sink" that distracts the drug away from the tumor.

The T cell compartment counts remained stable in absolute numbers, with a non-statistically significant trend towards reduction of the CD4+/CD8+ T cell ratio among BCMA-treated vs a trend towards increase among the talquetamab treated patients. Despite the numerical stability of total T cells counts, there were major changes in their phenotype. Regarding regulatory T cells (Tregs), anti-BCMA therapies were associated with a reduction of CD4+ Tregs and a trend towards an increase of CD8+ Tregs, whereas talquetamab induced a unique regulatory signature characterized by elevated CD28+CD57+CD4+Tregs among complete responders. Functional profiling revealed that T-cell senescence drastically outweighed exhaustion and anergy across all cohorts in both PB and BM. More specifically, CD4+ T cell senescence was increased after three cycles of treatment, mirrored by a decrease in the naïve/TEMRA (Terminally differentiated effector memory) ratio. Notably, patients who responded to talquetamab exhibited higher levels of CD4+ senescent T cells in both the BM and PB compared to the non-responders.

In conclusion, our data indicate that the profound, target-specific pressure on the immune microenvironment by BsAbs is associated with significant changes in the immune profile of MM patients. Anti-BCMA therapies disrupt normal B-cell maturation compared to anti-GPRC5D, while B cells may act as a target antigen sink due to their substantial BCMA expression, possibly affecting anti-BCMA BsAbs’ clinical efficacy. On the other hand, GPRC5D-targeted therapy is associated with the expansion of a distinct CD4+ regulatory T-cell pathway. In depth functional profiling reveals that T cell senescence, and not the predicted exhaustion, is the leading driver in the T cell compartment. Ongoing analysis of the current and additional cases will provide further insights into the immune profile of patients treated with BsAbs.

Konstantina Taouxi: No relevant conflicts of interest to declare.